Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Moderate alignment on mechanism, conversion to active drug, and some monitoring/interaction concepts; however, several claims are unsupported or potentially unsafe due to missing or non-supported label excerpts (notably missed-dose and pregnancy/trying-to-pregnant guidance) and formulation/indication mismatch (ATACAND HCT vs candesartan cilexetil).
Category Scores
Accurate Statements
Candesartan cilexetil is converted in the body to candesartan.
DESCRIPTION: “Following oral administration, candesartan cilexetil undergoes hydrolysis… to form the active drug, candesartan.”
Candesartan cilexetil blocks the angiotensin II type 1 (AT1) receptor.
CLINICAL PHARMACOLOGY: “selectively blocking the binding of angiotensin II to the AT1 receptor.”
Clinicians monitor for increased potassium with candesartan cilexetil.
Drug Interactions: “Co-administration… potassium supplements… or other drugs that raise serum potassium… may result in hyperkalemia. Monitor serum potassium…”
Clinicians monitor for effects on kidney function with candesartan cilexetil.
Impaired Renal Function: “Monitor renal function periodically…”
Patients are advised to use caution and have monitoring if they take potassium supplements or salt substitutes that contain potassium with candesartan cilexetil.
Drug Interactions: “potassium supplements or potassium-containing salt substitutes… may result in hyperkalemia. Monitor serum potassium…”
NSAIDs may affect kidney function in some patients taking candesartan cilexetil.
Drug Interactions: “co-administration of NSAIDs… may result in deterioration of renal function, including possible acute renal failure. Monitor renal function periodically…”
Taking too much candesartan cilexetil can increase the risk of low blood pressure.
OVERDOSAGE: “most likely manifestations… hypotension”
Taking too much candesartan cilexetil can cause symptoms such as dizziness.
OVERDOSAGE: “most likely manifestations… hypotension, dizziness, and tachycardia”
Unsupported Statements
Candesartan cilexetil is used to treat high blood pressure (hypertension).
Only provided hypertension/blood-pressure-lowering indication is for ATACAND HCT (combination). Supplied excerpts do not clearly establish the same indication wording for candesartan cilexetil monotherapy.
Candesartan cilexetil may be used in heart failure.
No heart failure indication is present in the supplied label excerpts.
Candesartan cilexetil may be used to help protect the heart in appropriate patients.
No “heart protection” claim/indication is present in the supplied label excerpts.
An 8 mg dose of candesartan cilexetil is usually prescribed as a fixed tablet strength.
Provided DOSAGE/strength details in excerpts do not identify an “8 mg” fixed tablet strength for candesartan cilexetil.
Some patients start at a lower dose and may be titrated upward under clinician supervision.
Titration concepts are present, but the supplied excerpts do not explicitly support the generalized “some patients start at a lower dose” phrasing for candesartan cilexetil in general.
Common side effects of candesartan cilexetil can include headache.
Headache is not mentioned in the supplied label excerpts as a side effect.
Common side effects of candesartan cilexetil can include tiredness.
Tiredness is not mentioned in the supplied label excerpts as a side effect.
Common side effects of candesartan cilexetil can include gastrointestinal effects.
Gastrointestinal effects are not mentioned in the supplied label excerpts as a side effect.
People who are pregnant or trying to become pregnant generally should not take ARBs.
Pregnancy guidance is not present in the supplied label excerpts.
If a dose of candesartan cilexetil is missed, the usual approach is to take it when remembered unless it is close to the next scheduled dose.
Missed-dose instructions are not present in the supplied label excerpts.
When a dose is missed, patients should not double up with candesartan cilexetil.
Missed-dose/doubling guidance is not present in the supplied label excerpts.
Taking too much candesartan cilexetil can cause symptoms such as fainting.
Overdosage manifestations listed in the supplied excerpts do not include fainting.
Candesartan cilexetil is widely available as a generic in many markets.
Not addressed in the supplied label excerpts (non-label factual claim).
Contradictions
Important Omissions
Pregnancy/trying-to-become-pregnant safety guidance for ARBs (e.g., pregnancy contraindication/boxed warning content).
Importance:
High
Missed-dose and administration instructions (treatment/behavior when a dose is missed).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Risk arises from unsupported/label-missing safety topics (pregnancy guidance) and unsupported missed-dose administration instructions; also includes formulation/label-scope mismatch for hypertension (ATACAND HCT vs candesartan cilexetil) and unsupported adverse-effect and dosing-strength claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several key claims are unsupported by the provided label excerpts, especially missed-dose instructions and pregnancy-related guidance, and there is potential scope mismatch between ATACAND HCT label text and candesartan cilexetil monotherapy claims.
Suggested Improvement
Limit assertions strictly to content contained in the supplied FDA label excerpts (including noting when statements pertain to ATACAND HCT vs candesartan cilexetil), remove/replace unsupported adverse-effect/common side-effect, missed-dose, pregnancy, and fixed 8 mg strength claims unless supported by the provided label text.